Pemetrexed in second line and beyond small cell lung cancer: A hoosier oncology group phase II study

Keyphrases

• Small Cell Lung Cancer 100%
• Phase II Study 100%
• Oncology 100%
• Pemetrexed 100%
• Chemotherapy 60%
• Chemotherapy Resistance 40%
• Partial Response 40%
• Stable Disease 40%
• Progressive Disease 40%
• Lung 20%
• Performance Status 20%
• Chemosensitive 20%
• Advanced Disease 20%
• First-line Therapy 20%
• Poor Differentiation 20%
• Targeted Agents 20%
• Systemic Therapy 20%
• Recurrent Disease 20%
• Prior Chemotherapy 20%
• Chemotherapy Regimen 20%
• Drug Resistance 20%
• Survival Time 20%
• Best Response 20%
• Vitamin B12 20%
• Antimetabolites 20%
• Folic Acid 20%
• Sensitive Diseases 20%
• Therapy-resistant 20%
• First-line Chemotherapy 20%
• Agent Behavior 20%
• Eastern Cooperative Oncology Group Performance Status (ECOG PS) 20%
• Sensitive Groups 20%
• Clinical Benefit Rate 20%
• Neuroendocrine Cancer 20%
• Chemorefractory 20%
• Sensitive Relapse 20%
• Steroid Prophylaxis 20%

Medicine and Dentistry

• Oncology 100%
• Small Cell Lung Cancer 100%
• Pemetrexed 100%
• Diseases 80%
• Arm 40%
• Progressive Disease 40%
• Cancer 20%
• Drug Resistance 20%
• Recurrent Disease 20%
• Systemic Therapy 20%
• Patient History of Chemotherapy 20%
• Antimetabolite 20%
• Folic Acid 20%
• Survival Time 20%
• First-Line Chemotherapy 20%
• Lung 20%
• Chemotherapy 20%
• Vitamin B12 20%